Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAIF: rhBSSL for Growth in Preterm Infants
NCT01413581Phase 3Terminated
- Sponsor
- Sobi
- Start
- May 2011
- Primary completion
- Jul 2013
- Modality
- Replacement Enzymes
- Countries
- 10
01
Overview
A Phase 3 trial of bucelipase alfa in intrauterine growth restriction (IUGR), sponsored by Sobi. Started May 2011; status: terminated.
02
Drugs
bucelipase alfa
03
Conditions
intrauterine growth restriction (IUGR)
Beyond the preview
Go deeper on NCT01413581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01413581.